Renaissance Technologies LLC Has $18.40 Million Stock Holdings in Vera Therapeutics, Inc. $VERA

Renaissance Technologies LLC raised its stake in Vera Therapeutics, Inc. (NASDAQ:VERA) by 136.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 457,300 shares of the company’s stock after purchasing an additional 263,900 shares during the quarter. Renaissance Technologies LLC’s holdings in Vera Therapeutics were worth $18,397,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in VERA. Price T Rowe Associates Inc. MD raised its stake in shares of Vera Therapeutics by 49.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock worth $276,595,000 after purchasing an additional 1,795,537 shares in the last quarter. Vestal Point Capital LP grew its stake in shares of Vera Therapeutics by 24.0% in the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after buying an additional 600,000 shares in the last quarter. Elmind Capital LP acquired a new position in Vera Therapeutics during the fourth quarter worth $24,434,000. Armistice Capital LLC increased its holdings in Vera Therapeutics by 294.1% during the third quarter. Armistice Capital LLC now owns 536,000 shares of the company’s stock worth $15,576,000 after buying an additional 400,000 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Vera Therapeutics by 11.9% during the fourth quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock worth $180,805,000 after acquiring an additional 379,748 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on VERA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Friday, July 17th. Bank of America upped their target price on shares of Vera Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. Needham & Company LLC set a $125.00 target price on shares of Vera Therapeutics in a research note on Wednesday, July 8th. Evercore set a $91.00 price target on Vera Therapeutics in a report on Friday, May 15th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $90.00 price target on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.58.

Vera Therapeutics Stock Performance

Shares of VERA stock opened at $33.05 on Friday. The company has a market capitalization of $2.37 billion, a price-to-earnings ratio of -5.97 and a beta of 0.92. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. The company has a 50-day simple moving average of $36.95 and a 200 day simple moving average of $39.68. Vera Therapeutics, Inc. has a 52 week low of $19.07 and a 52 week high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the previous year, the company earned ($0.81) EPS. On average, sell-side analysts predict that Vera Therapeutics, Inc. will post -6.37 earnings per share for the current year.

Insider Activity

In other news, CEO Marshall Fordyce sold 46,250 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total value of $1,956,375.00. Following the transaction, the chief executive officer owned 151,994 shares of the company’s stock, valued at approximately $6,429,346.20. This represents a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 83,250 shares of company stock worth $3,337,770 in the last three months. Insiders own 15.90% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.